Four independent pharmacies in three states filed a class-action lawsuit last week alleging Express Scripts of colluding with Prime Therapeutics to charge higher fees and reimburse pharmacies at lower rates. The complaint, which claims violation of the Sherman Act, argues "that a three-year collaboration agreement announced in 2019 between Express Scripts and Prime Therapeutics was in fact a pretext for fixing reimbursement rates and fees, with no benefit for customers," according to Reuters.
The pharmacies — two in Wisconsin, one in Minnesota, and one in New Jersey — claim "the Agreement does not, and is not intended to, achieve any efficiencies or economies of scale or procompetitive effects in the relevant markets, and the assertion of any such efficiencies or procompetitive effects by either Prime or [Express Scripts] is pretextual," according to the lawsuit, which was filed in Milwaukee federal court. "The Agreement is simply a naked restraint on price competition with regard to Reimbursement Rates and Transaction Fees."
Cigna-owned Express Scripts is one of the largest pharmacy benefit managers in the United States and in April announced efforts to expand health care in rural communities through partnerships with independent pharmacies across the country with "increased reimbursement opportunities."
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.